EGFR and non-small cell lung carcinoma: In 2011, Shukuya et al. [19] carried out a pooled analysis of published reports regarding the efficacy of gefitinib for use in non-adenocarcinoma, non-small cell lung cancer patients harboring EGFR mutations.